News Focus
News Focus
Replies to #65429 on Biotech Values
icon url

zipjet

08/18/08 5:37 PM

#65431 RE: DewDiligence #65429

>>DYAX – Your buddy, Jason Kolbert, is quoted again :- )

If he has the facts right, that CSL's C1 inh has been delayed - then that is news to me. Good news.

The blind squirrel found an acorn.

:-)

Hope he is right this time.

ij


There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)
icon url

rkrw

08/18/08 11:43 PM

#65441 RE: DewDiligence #65429

Why do I suspect its like Mike Barnicle when he would quote fictitious people.

<<<"From our conversations with HAE patients, we know that they prefer subcutaneous therapy," >>>

Not saying he's wrong, for acute attacks, if all else were equal. But I'd love to know what his sample size is.

icon url

genisi

09/24/08 11:22 AM

#66575 RE: DewDiligence #65429

Dyax announced completion of BLA for DX-88 for HAE and has requested Priority Review. With a 6 month review, launch can be expected in mid 09.